Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 595
- Registration Number
- NCT00061750
- Locations
- πΊπΈ
Stanford Hospital, Stanford, California, United States
πΊπΈChildren's Hospital Oakland, Oakland, California, United States
πΊπΈChildren's Hospital Boston, Boston, Massachusetts, United States
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
- Conditions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT00061763
- Locations
- πΊπΈ
Stanford Hospital, Stanford, California, United States
πΊπΈChildren's Hospital Boston, Boston, Massachusetts, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-14
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 855
- Registration Number
- NCT00056446
- Locations
- πΊπΈ
UCLA School of Medicine, Los Angeles, California, United States
πΊπΈOwensboro Medical Health System, Owensboro, Kentucky, United States
πΊπΈColumbus CCOP, Columbus, Ohio, United States
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
- Conditions
- Interventions
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT00052013
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT00051636
- Locations
- π¬π§
Novartis Investigative Site, Vale of Glamorgan, United Kingdom
π¬π§Novartis investigative site, Pernarth, United Kingdom
π¬π§Novartis Investigative site, Penarth, United Kingdom
Pediatric Epilepsy Study
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT00050934
- Locations
- π²π½
Novartis, Mexico City, Mexico
π§π·Brigadeiro Hospital, Sao Paulo - SP, Brazil
Pediatric Epilepsy Study
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 94
- Registration Number
- NCT00050947
- Locations
- π²π½
Novartis, Mexico City, Mexico
π§π·Brigadeiro Hospital, Sao Paulo - SP, Brazil
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT00050635
- Locations
- πΊπΈ
Creticos Cancer Center, Chicago, Illinois, United States
πΊπΈDecatur Memorial Hospital, Decatur, Illinois, United States
πΊπΈOncology Hematology Group of South Florida, Miami, Florida, United States
EPO906 in Carcinoid and Other Neuroendocrine Tumors
- First Posted Date
- 2002-12-05
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT00050349
- Locations
- πΊπΈ
Oregon Health Sciences University, Portland, Oregon, United States
πΊπΈLSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2), New Orleans, Louisiana, United States
πΊπΈUniversity of Iowa Health Care, Iowa City, Iowa, United States
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2002-11-20
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 602
- Registration Number
- NCT00050011
- Locations
- πΊπΈ
FL Community Cancer Center, Brooksville, Florida, United States
πΊπΈEastern Connecticut Hematology/Oncology Associates, Norwich, Connecticut, United States
πΊπΈElmhurst Memorial Hospital, Elhurst, Illinois, United States